CureDM

What CureDM does

CureDM is a privately held biopharmaceutical company founded in 2004 and based in Wilmington, Delaware. According to its firmographic description, the company is developing therapies intended to prevent, ameliorate, and reverse diabetes — positioning it in the metabolic disease therapeutics space with an ambitious disease-modifying (rather than symptom-management) thesis.

Operationally, the company is extremely small, with 1-10 employees, and has maintained a low public profile. The company has executed limited but identifiable strategic actions: two early-stage funding rounds totaling approximately $4.6M (a $2.5M round in November 2006 led by Scientific Health Development Partners with Calvert Research Institute, and a $2.1M round in August 2009 with undisclosed investors), and the acquisition of AviaraMD in September 2013 for an undisclosed amount. Rita El-Hajj is documented as founder.

The current public information on CureDM is notably thin: the corporate website displays only a loading/verification page rather than substantive content, no products or services are publicly enumerated, no pricing or revenue model is disclosed, no current management team beyond the founder is listed, and no partnerships, awards, patents, or clinical milestones are recorded in the available data. This combination of factors — minimal headcount, a 15+ year gap since the last documented financing, a non-functional web presence, and absence of disclosed commercial or clinical activity — suggests the company is either dormant, operating in stealth, or at a very early pre-clinical stage with limited external visibility.

Name

CureDM

Website

https://curedm.com

Company type

Private

Founded year

2004

Headcount range

1–10 employees

Short description

CureDM is a privately held biopharmaceutical company founded in 2004 in Wilmington, Delaware, developing therapies intended to prevent, ameliorate, and reverse diabetes. The company has 1-10 employees and has raised approximately $4.6M across two early-stage rounds.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)

akta.pro secondary industry

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

Keywords

• Diabetes therapeutics
• Metabolic disease drugs
• Biopharmaceutical research
• Peptide therapeutics
• Clinical stage biopharma

Headquarters

HQ city

Wilmington

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Core offering

CureDM is a biopharmaceutical company developing therapeutic candidates designed to prevent, ameliorate, and reverse diabetes. The company focuses on metabolic disease drug discovery, operating as a clinical-stage developer that conducts R&D on novel diabetes therapies, including proprietary assets obtained through its 2013 acquisition of AviaraMD.

Differentiator

Problem solved

Functional benefit

Products and services

• Diabetes therapeutic pipeline (disease-modifying therapies) Therapeutic candidates in development at CureDM intended to prevent, ameliorate, and reverse diabetes, targeting the underlying mechanisms of the disease rather than chronic symptomatic management. Targeted at the metabolic disease therapeutics market and intended for eventual out-licensing or partnership with larger pharmaceutical commercialization counterparts.

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights2 records

Broad incumbents

• Eli Lilly: Eli Lilly is a major incumbent in diabetes with a broad metabolic portfolio including Mounjaro/Zepbound and a long history of insulin products. The dominant large-pharma competitor and likely acquirer/partner in this space.
• Sanofi: Sanofi is a major incumbent in diabetes (Lantus, Toujeo, Amaryl) with broad metabolic and biologics capabilities. A likely strategic partner or acquirer profile for any small diabetes-biologics company.
• Novo Nordisk: Novo Nordisk is the global leader in diabetes care with the dominant insulin and GLP-1 franchises. Serves as the incumbent benchmark for any company developing diabetes biologics.

Direct peers

• MannKind Corporation: MannKind developed and commercialized Afrezza, an inhaled insulin therapy for diabetes, and focuses on endocrine/metabolic disease. Comparable small-cap biotech pursuing innovative diabetes therapeutics.
• DiaMedica Therapeutics: DiaMedica is a clinical-stage biopharma developing recombinant protein therapeutics, historically with diabetes programs (DM199/KLK1). Directly comparable as a small recombinant-protein biotech in metabolic disease.
• Oramed Pharmaceuticals: Oramed is a clinical-stage biopharma developing oral insulin and other protein-based diabetes therapies. Directly comparable to CureDM as a small-cap biotech pursuing novel biologic / peptide approaches to diabetes treatment.
• Provention Bio: Provention Bio developed biologic therapies targeting immune-mediated and metabolic diseases including type 1 diabetes (teplizumab). Comparable as a small biopharma pursuing biologic approaches to diabetes.
• Lexicon Pharmaceuticals: Lexicon developed and commercialized a SGLT2 inhibitor for type 2 diabetes (sotagliflozin) and is a small-cap biotech with metabolic disease focus. Comparable as a diabetes-focused biopharma with biologic/small-molecule assets.
• vTv Therapeutics: vTv Therapeutics is a small clinical-stage biotech that has pursued disease-modifying approaches in diabetes and other metabolic indications. Comparable in stage, size, and therapeutic focus on novel diabetes mechanisms.

Emerging players

• Inversago Pharma: Inversago is a clinical-stage biotech developing peripherally-acting CB1 receptor blockers for metabolic disorders including diabetes. Comparable as an emerging player in novel-mechanism metabolic biologics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/curedm-group-holdings-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CureDM